Duovent | 438627-66-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: Duovent
• 英文别名: 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;(8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;bromide
• CAS: 438627-66-8
• 化学式: C33H51BrN2O6
• 分子量: 651.7
• InChiKey: FYTIZSKUAAWPPR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  119
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• SUSPENSION FORMULATIONS
  申请人：Lewis David Andrew

  公开号：US20110182997A1

  公开（公告）日：2011-07-28

  The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

  本发明涉及悬浮液配方，特别是用于使用喷雾或气雾装置以气雾形式传递药物活性剂的配方，例如压力计量剂量吸入器（pMDI）。这些配方可以用于肺部、鼻部、颊部或局部给药，但最好用于肺部吸入。
• CONTROL UNIT FOR USE WITH A RESPIRATORY ASSIST DEVICE
  申请人：Koninklijke Philips N.V.

  公开号：EP3520848A1

  公开（公告）日：2019-08-07

  There is provided a control unit (100) for use with a respiratory assist device (102) that assists a subject (104) with respiration. The control unit (100) configured to detect a time at which delivery of an inhalable therapy to the subject (104) is manually triggered on an inhalable therapy device (106). The control unit (100) is also configured to detect whether the subject (104) has fallen asleep and, on detecting that the subject (104) has fallen asleep, control the inhalable therapy device (106) to automatically trigger delivery of the inhalable therapy to the subject (104) at least a predefined length of time following the detected time at which delivery of the inhalable therapy to the subject (104) is manually triggered.

  提供了一种与呼吸辅助装置（102）一起使用的控制单元（100），该装置可帮助受试者（104）进行呼吸。控制单元 (100) 配置为检测在可吸入治疗装置 (106) 上手动触发向受试者 (104) 输送可吸入治疗的时间。控制单元（100）还配置为检测受试者（104）是否已经入睡，并在检测到受试者（104）已经入睡时，控制可吸入治疗装置（106）自动触发向受试者（104）输送可吸入治疗的时间，至少在检测到向受试者（104）输送可吸入治疗的时间被手动触发后的预定时间长度内。
• Method of treating allergen induced airway disease
  申请人：——

  公开号：US20040033209A1

  公开（公告）日：2004-02-19

  The invention features methods of treating allergic asthma by administering to a subject a chimeric polypeptide that comprises a first polypeptide domain comprising at least one moiety that specifically binds to a chemokine receptor; and, a second polypeptide domain comprising at least one of (a)-(d): (a) a moiety that binds to a T cell surface polypeptide, (b) a moiety that binds to a dendritic cell surface polypeptide, (c) a moiety that binds to a cell toxin, or (d) a cell toxin.

  本发明的特征是通过给受试者施用嵌合多肽来治疗过敏性哮喘的方法，嵌合多肽包括第一多肽结构域，该结构域包含至少一个能与趋化因子受体特异性结合的分子；以及第二多肽结构域，该结构域包含(a)-(d)中的至少一个：(a) 与 T 细胞表面多肽结合的分子；(b) 与树突状细胞表面多肽结合的分子；(c) 与细胞毒素结合的分子；或 (d) 细胞毒素。
• USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
  申请人：Biogen Idec MA Inc.

  公开号：EP1855711A2

  公开（公告）日：2007-11-21
• KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS
  申请人：Biogen Idec MA Inc.

  公开号：EP1865985B1

  公开（公告）日：2010-08-25